TITUSVILLE, N.J., April 24, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care (LINCC(TM)) Initiative. The LINCC(TM) Initiative is part of the Janssen Therapeutics commitment to improving access to care in ... read more
TITUSVILLE, N.J., Dec. 31, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to SIRTURO(TM) (bedaquiline) Tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval ... read more
TITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the ... read more